Friday, April 3, 2026
31.5 C
Bengaluru

Ashok Nair, Managing Director of Abbott India in Conversation with MedicinMan

https://www.credoweb.in/discussion/661/new-growth-drivers-for-indian-pharma-companies

Ashok Nair began his career as a Medical Rep and rose to become the Managing Director of one of India’s most admired pharma companies – Abbott India.

In this conversation, Ashok Nair shares his perspectives on the challenges ahead and what Indian Pharma needs to do, to face them effectively.

Register now to receive your invitation to the webinar on 1st May 2021

Over 20 pharma leaders have shared their perspectives on various aspects of pharma business, you can register and view them at any time on

www.credoweb.in

Hot this week

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Topics

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?

As over 50 generic versions of the blockbuster weight-loss...

Excellence or Mediocrity—What Are You Building?

Excellence is a choice. So is Mediocrity Excellence is a...
spot_img

Related Articles

spot_imgspot_img